Literature DB >> 19540477

Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial.

Kelly Pagidas1, Sandra A Carson2, Peter G McGovern3, Huiman X Barnhart4, Evan R Myers5, Richard S Legro6, Michael P Diamond7, Bruce R Carr8, William D Schlaff9, Christos Coutifaris10, Michael P Steinkampf11, Nicholas A Cataldo12, John E Nestler13, Gabey Gosman14, Linda C Giudice15.   

Abstract

OBJECTIVE: To investigate the relationship among intercourse compliance, ovulation, and the occurrence of pregnancy in the Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (RMNPPCOS) Trial.
DESIGN: Post hoc data analysis of subjects in the Reproductive Medicine Network PPCOS Trial.
SETTING: Academic medical centers. INTERVENTION(S): None. PATIENT(S): Six hundred twenty-six infertile women with polycystic ovary syndrome with a mean age of 28.1+/-4 years and mean body mass index of 35.2+/-8.7 kg/m2. MAIN OUTCOME MEASURE(S): Intercourse compliance, ovulation, and pregnancy. RESULT(S): Data on 2925 cycles were included in the analysis, of which 1340 were ovulatory cycles and 1585 were nonovulatory cycles. The rates of intercourse compliance in the PPCOS trial were similar across all treatment groups at all cycles except cycle 4. Among cycles with known ovulation status, 81.2% of patients were compliant with intercourse instructions. Patients were more intercourse compliant in those cycles during which ovulation occurred (83.2% vs. 79.4%). With regard to ovulatory cycles, there was no difference in the occurrence of pregnancy when comparing intercourse compliant versus intercourse noncompliant cycles. CONCLUSION(S): Intercourse compliance was not associated with the occurrence of pregnancy in ovulatory cycles in the PPCOS Trial. The occurrence of ovulation still remains a critical predictor for the occurrence of pregnancy. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540477      PMCID: PMC2891817          DOI: 10.1016/j.fertnstert.2009.05.047

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  Ovarian function in the preovulatory rabbit.

Authors:  C H Wu; L Blasco; G L Flickinger; G Mikhail
Journal:  Biol Reprod       Date:  1977-09       Impact factor: 4.285

2.  Psychoendocrinological assessment of the menstrual cycle: the relationship between hormones, sexuality, and mood.

Authors:  S H Van Goozen; V M Wiegant; E Endert; F A Helmond; N E Van de Poll
Journal:  Arch Sex Behav       Date:  1997-08

3.  The influence of androstenol - a putative human pheromone - on mood throughout the menstrual cycle.

Authors:  D Benton
Journal:  Biol Psychol       Date:  1982 Nov-Dec       Impact factor: 3.251

4.  Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.

Authors:  Stefano Palomba; Francesco Orio; Angela Falbo; Francesco Manguso; Tiziana Russo; Teresa Cascella; Achille Tolino; Enrico Carmina; Annamaria Colao; Fulvio Zullo
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

5.  Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.

Authors:  Richard S Legro; Huiman X Barnhart; William D Schlaff; Bruce R Carr; Michael P Diamond; Sandra A Carson; Michael P Steinkampf; Christos Coutifaris; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Linda C Giudice; Phyllis C Leppert; Evan R Myers
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

  5 in total
  4 in total

1.  The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.

Authors:  Richard S Legro; Allen R Kunselman; Robert G Brzyski; Peter R Casson; Michael P Diamond; William D Schlaff; Gregory M Christman; Christos Coutifaris; Hugh S Taylor; Esther Eisenberg; Nanette Santoro; Heping Zhang
Journal:  Contemp Clin Trials       Date:  2012-01-13       Impact factor: 2.226

2.  Sexual activity, endogenous reproductive hormones and ovulation in premenopausal women.

Authors:  Ankita Prasad; Sunni L Mumford; Germaine M Buck Louis; Katherine A Ahrens; Lindsey A Sjaarda; Karen C Schliep; Neil J Perkins; Kerri A Kissell; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  Horm Behav       Date:  2014-06-20       Impact factor: 3.587

3.  The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial.

Authors:  Richard S Legro; Robert G Brzyski; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; Hao Huang; Qingshang Yan; Daniel J Haisenleder; Kurt T Barnhart; G Wright Bates; Rebecca Usadi; Richard Lucidi; Valerie Baker; J C Trussell; Stephen A Krawetz; Peter Snyder; Dana Ohl; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2013-10-21       Impact factor: 7.329

4.  Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth.

Authors:  Lawrence Engmann; Fangbai Sun; Richard S Legro; Michael P Diamond; Heping Zhang; Nanette Santoro
Journal:  Hum Reprod       Date:  2020-12-01       Impact factor: 6.918

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.